Exscientia, a developer of automated drug discovery technologies, agreed to acquire Allcyte, a developer of a pharmacology high-content imaging platform, for $59m. “Allcyte is able to demonstrate what therapy actually works in the individual patient with the most disease relevant screening platform we have seen. Combining Allcyte’s platform with Exscientia’s technologies can redefine how drugs are developed, enabling integrated discovery and patient selection. Allcyte has assembled an outstanding team in Vienna and integration of the two platforms truly allows us to build our vision of patient-first AI," Andrew Hopkins, Exscientia CEO.